Skip to main content

Centogene CentoCancer and CentoCard

Centogene has launched CentoCancer and CentoCard. CentoCancer is a 31 gene panel that identifies an elevated risk of significant hereditary cancers including breast, ovarian, gastric, colon, endometrial, prostate, pancreatic, renal, liver, and skin cancer. CentoCard is a sample collection system that can be used to extract high-quality DNA to perform any genetic test, the company said. Once samples are dry, they are considered stable and can be mailed through regular post without special declaration.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.